Screen for perinatal depression with the EPDS questionnaire. 10-item validated scale for postpartum, antenatal, and paternal depression screening.
The Edinburgh Postnatal Depression Scale (EPDS) Calculator implements the widely used 10-item self-report questionnaire for screening perinatal depression in mothers and fathers. Developed by Cox, Holden, and Sagovsky in 1987, the EPDS is recommended by ACOG, the APA, and the US Preventive Services Task Force (USPSTF) for routine perinatal depression screening. It has been validated in over 60 languages across diverse populations.
Postpartum depression affects approximately 10–15% of mothers and 5–10% of fathers within the first year after delivery. The EPDS screens for depressive symptoms experienced over the past 7 days, including inability to laugh, loss of enjoyment, self-blame, anxiety, panic, feeling overwhelmed, sleep difficulty due to unhappiness, sadness, crying, and thoughts of self-harm. Each item is scored 0–3, yielding a total score of 0–30.
A score of ≥10 is the widely accepted threshold for postpartum screening (sensitivity ~86%, specificity ~78%). For antenatal screening, a threshold of ≥13 is sometimes used due to higher baseline anxiety in pregnancy. The EPDS is a screening tool — not a diagnostic instrument — and positive screens require clinical follow-up for diagnosis. Question 10 regarding self-harm thoughts requires immediate safety assessment regardless of total score.
Perinatal depression is underdiagnosed — up to 50% of cases are missed without systematic screening. The EPDS specifically focuses on the cognitive and emotional components of depression (rather than somatic symptoms like fatigue and appetite changes that are normal in the postpartum period), making it more appropriate than general depression scales like the PHQ-9 for perinatal populations.
EPDS Total Score = Sum of all 10 items (each scored 0–3) Range: 0–30 Screening thresholds: • Postpartum: ≥10 (positive screen) • Antenatal: ≥13 (positive screen) Subscales: • Anxiety: Questions 3, 4, 5 • Depression: Questions 1, 2, 8, 9 • Self-harm: Question 10 Sensitivity: ~86% at threshold ≥10 Specificity: ~78% at threshold ≥10
Result: EPDS Score: 13 — Likely depression, refer for evaluation
Total score 13 is above the postpartum threshold of ≥10. Anxiety subscore (Q3+Q4+Q5) = 5/9 suggests significant anxiety. Depression subscore (Q1+Q2+Q8+Q9) = 5/12. Q10 = 0 (no self-harm). Referral for clinical diagnostic evaluation is recommended. The elevated anxiety subscore suggests screening for comorbid anxiety disorder.
The EPDS was developed in 1987 by John Cox (psychiatrist), Jeni Holden (health visitor), and Ruth Sagovsky (research psychologist) in Edinburgh and Livingston, Scotland. It was created because existing depression scales (Beck Depression Inventory, Zung Scale) had poor performance in postnatal populations due to inclusion of somatic items that overlap with normal postpartum experiences. The original validation study in the British Journal of Psychiatry established the ≥13 threshold for "definite" depression and ≥10 for "possible" depression. The ≥10 threshold has become the standard in most clinical settings.
Successful EPDS implementation requires: training staff on administration and scoring, establishing a referral pathway for positive screens, ensuring timely follow-up (within 1–2 weeks for scores 10–12, within 1 week for ≥13, immediately for Q10 >0), and documenting screening and outcomes. Electronic health record integration with automatic scoring and alerts improves implementation. The EPDS is freely available without licensing fees for clinical and research use.
The EPDS has been translated into over 60 languages and validated across diverse cultural settings. However, cultural factors affect disclosure — in some cultures, acknowledging mental health difficulties carries significant stigma. Research suggests the EPDS may underestimate depression prevalence in certain cultural groups. Healthcare providers should use culturally sensitive approaches, ensure translated versions are linguistically validated (not just word-for-word translations), and consider that the optimal threshold may vary across populations.
"Baby blues" affect 50–80% of new mothers, featuring mood swings, tearfulness, irritability, and anxiety in the first 2 weeks after delivery — they resolve spontaneously. Postpartum depression (PPD) is more severe, lasts longer (weeks to months without treatment), and includes persistent sadness, loss of interest, guilt, sleep and appetite disturbance, difficulty bonding with the baby, and sometimes thoughts of self-harm. PPD requires treatment (therapy, medication, or both).
ACOG and USPSTF recommend at least: once during pregnancy (first prenatal visit or early third trimester) and once postpartum (6–12 week visit). Many practices screen at 1 week, 4–6 weeks, 3 months, and 6 months postpartum. Screening should also occur at any visit where depressive symptoms are suspected. The EPDS asks about the past 7 days, so repeated screening captures evolving symptoms.
Yes — the EPDS has been validated for paternal perinatal depression (PPD in fathers), which affects 5–10% of new fathers. The same threshold of ≥10 is used. Paternal PPD often presents differently than maternal PPD — more irritability, withdrawal, substance use, and risk-taking behavior. Screening both parents is increasingly recommended, as paternal PPD is strongly associated with maternal PPD.
Evidence-based treatments include: psychotherapy (CBT and IPT are first-line, with similar efficacy to medication), antidepressants (SSRIs — sertraline and paroxetine have the most safety data in breastfeeding), and brexanolone (Zulresso) — an IV neuroactive steroid specifically FDA-approved for PPD. New oral neurosteroid zuranolone (Zurzuvae) was FDA-approved in 2023 for PPD with rapid onset (3 days). Severe cases may require psychiatric hospitalization.
The EPDS was developed and validated specifically for perinatal populations. For non-perinatal depression screening, the PHQ-9 is more widely used and validated. However, some clinics use the EPDS up to 12 months postpartum and beyond. The PHQ-9 is preferred for general adult depression screening because it maps directly to DSM-5 diagnostic criteria.
The EPDS (10 items, 0–30) was specifically designed for perinatal use — it avoids somatic symptoms (fatigue, appetite, sleep changes) that are normal in pregnancy/postpartum and focuses on emotional/cognitive symptoms. The PHQ-9 (9 items, 0–27) maps to DSM-5 criteria and includes somatic items, making it better for general adult populations but potentially less specific in perinatal settings where somatic symptoms are confounded by normal pregnancy/postpartum changes.